LAFAYETTE, LOUISIANA – February 27, 2020 – RedHawk Holdings Corp. (OTC: SNDD)
FOR IMMEDIATE RELEASE
Company Contact: G. Darcy Klug, Chairman, CEO and CFO (337) 269-5933 firstname.lastname@example.org
Investor Relations: Stephanie Prince, Managing Director PCG Advisory (646) 762-4518 email@example.com
Media Contact: Valerie Allen Valerie Allen Public Relations (310) 382-7800 firstname.lastname@example.org
REDHAWK PARTNERS WITH PELICAN ENGINEERING LLC FOR GMP MANUFACTURING OVERSIGHT
RedHawk Nearing Completion of Steps Necessary to Seek Medicare and Medicaid Accreditation
LAFAYETTE, LOUISIANA – February 27, 2020 – RedHawk Holdings Corp. (OTC: SNDD) (“RedHawk” or the “Company”) a diversified holding company engaged in sales and distribution of medical devices, branded generic pharmaceutical drugs, commercial real estate investment and leasing, point of entry full-body security systems, and specialized financial services, announced today that RedHawk Research & Development LLC, a wholly-owned subsidiary of the Company, has agreed to partner with Louisiana-based Pelican Engineering LLC (“Pelican”) for the supervision of the Company’s quality assurance and future research and development programs.
Pelican is a full-service electronics engineering design firm that provides engineering services and component manufacturing in all aspects of the electrical, electronics, and computer engineering disciplines. Primarily focused on embedded printed circuit board hardware and software development, Pelican is capable of in-house engineering, design, manufacturing, and turn-key delivery of high-quality embedded systems.
Pelican was instrumental in the redesign of the SANDD ProTM as well as the new printed circuit boards used in the SANDD mini – HPTM and the SANDD mini – FRTM. Separately, Pelican is also expected to lead the development and redesign of “Centri”, the Company’s controlled entry security system, a unique, closed cabinet, nominal dose transmission full-body x-ray scanner.
In June 2019, the Company announced the transition and ongoing maintenance of its current FDA-approved quality management system to the higher and more stringent international medical device standard, ISO 13485:2016. The Company believes it is now near completion of this previously announced quality management transition and has now partnered with Pelican to develop and supervise the quality assurances testing believed necessary to maintain adherence to the stringent standards of ISO 13485:2016.
ISO 13485:2016 specifies global requirements for a quality management system where an organization must demonstrate its ability, and the ability of its suppliers, to provide medical devices and related services that consistently meet customer and applicable international regulatory requirements. ISO 13485 was specifically developed with the objective of harmonizing medical device regulatory requirements for quality management systems in major markets around the world including the United States, Europe, Canada, Japan and Australia. ISO 13485 meets, or exceeds, all U.S. Food and Drug Administration Quality System Regulations Standard 21 CFR 820 which was established in 1978 to outline Current Good Manufacturing Practices (GMP) in the United States.
Commenting on the partnership with Pelican, G. Darcy Klug, RedHawk’s Chairman and Interim Chief Executive Officer, said “We believe the previously announced partnership with the CKRX Enterprise sales organization positions us well for the commercial launch of our SANDDTM line of needle incineration products. Our next marketing focus is the consumer launch of the SANDDTM line of needle incineration devices. To properly position RedHawk for the consumer market, we believe we need to obtain Durable Medical Equipment (“DME”) Accreditation of our quality assurance program. The transition of our quality assurance program to ISO 13485:2016 and the completion of the quality assurance partnership with Pelican is the next step in preparing for DME Accreditation.”
“DME Accreditation is necessary for RedHawk to obtain a DME supplier license,” continued Mr. Klug. “With Pelican’s support, we believe that we are now positioned to seek the necessary DME Accreditation approvals. With DME Accreditation, we anticipate our customers will be eligible to receive Medicare, Medicaid or insurance company reimbursement for the purchase of our SANDDTM line of needle incineration devices. Obtaining these approvals would be a major milestone on the path for RedHawk to continue executing on its business model.”
# # #
About RedHawk Holdings Corp.
RedHawk Holdings Corp., formerly Independence Energy Corp., is a diversified holding company which, through its subsidiaries, is engaged in the sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full- body security systems, and specialized financial services. Through its medical products business unit, the Company sells the Sharps and Needle Destruction Device (SANDDTM), WoundClot Surgical – Advanced Bleeding Control, and the Carotid Artery Digital Non-Contact Thermometer. Through our United Kingdom based subsidiary, we manufacture and market branded generic pharmaceuticals. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full-body x-ray scanner. For more information, please visit: http://www.redhawkholdingscorp.com
Cautionary Statement Regarding Forward-Looking Statements
This release may contain forward-looking statements. Forward-looking statements are all statements other than statements of historical fact. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. The words “anticipate,” “may,” “can,” “plans,”
“believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be,” “potential” and any similar expressions are intended to identify those assertions as forward-looking statements.
Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties. In evaluating forward-looking statements, you should consider the various factors which may cause actual results to differ materially from any forward-looking statements including those listed in the “Risk Factors” section of our latest 10-K report. Further, the Company may make changes to its business plans that could or will affect its results. Investors are cautioned that the Company will undertake no obligation to update any forward-looking statements.